| Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi |
NCT01262846: Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals |
|
|
| Completed | 4 | 195 | US | Fluzone® | University of Pennsylvania | HIV Infection | 04/11 | 04/11 | | |
NCT01430819: Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults |
|
|
| Completed | 4 | 300 | US | Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation, Fluzone® 2011-2012 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation, Fluzone® High-Dose 2011-2012 Formulation | Sanofi Pasteur, a Sanofi Company | Influenza | 02/12 | 02/12 | | |
NCT01691339: Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults. |
|
|
| Completed | 4 | 200 | US | Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation, Fluzone® (2012-2013 Formulation), Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation, Fluzone® Intradermal (2012-2013 Formulation), Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation, Fluzone® High-Dose (2012-2013 Formulation) | Sanofi Pasteur, a Sanofi Company | Influenza | 11/12 | 02/13 | | |
NCT01427309: A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults |
|
|
| Completed | 4 | 31989 | US, Canada | High Dose Trivalent Inactivated Influenza Vaccine, Fluzone® High Dose, Trivalent Inactivated Influenza Vaccine, Fluzone® | Sanofi Pasteur, a Sanofi Company | Influenza | 05/13 | 11/13 | | |
NCT01720277: High Dose Influenza Vaccine in Nursing Home - Pilot Study |
|
|
| Completed | 4 | 2957 | US | HD Fluzone Vaccine, Fluzone High Dose influenza vaccine, SD Fluzone Vaccine, Fluzone influenza vaccine | Insight Therapeutics, LLC, Brown University | Influenza | 05/13 | 05/16 | | |
NCT01946438: Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults |
|
|
| Completed | 4 | 208 | US | Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® Quadrivalent, Influenza Virus Vaccine, Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® Intradermal, Influenza Virus Vaccine, Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation), Fluzone® High-Dose, Influenza Virus Vaccine | Sanofi Pasteur, a Sanofi Company | Influenza | 12/13 | 07/14 | | |
NCT02258334: Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults |
|
|
| Completed | 4 | 208 | US | Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone® Quadrivalent vaccine, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone® Intradermal vaccine, Fluzone High Dose vaccine, 2014-2015 formulation, Fluzone® High Dose, vaccine | Sanofi Pasteur, a Sanofi Company | Influenza | 11/14 | 12/14 | | |
| Completed | 4 | 136 | US | Trivalent, inactivated influenza vaccine (TIV), Fluzone (IM), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose), Fluzone High-Dose (IM) | Stanford University, National Institute of Allergy and Infectious Diseases (NIAID) | Influenza | 12/15 | 03/17 | | |
NCT02311855: Duration of Immune Response to Influenza Vaccination in Patients With RA |
|
|
| Completed | 4 | 87 | US | Influenza vaccine, Fluzone, Fluzone High Dose | Bassett Healthcare, New York State Department of Health | Rheumatoid Arthritis | 12/15 | 02/16 | | |
